140 related articles for article (PubMed ID: 35545174)
1. Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC.
Gross CP; Meyer CS; Ogale S; Kent M; Wong WB
J Natl Compr Canc Netw; 2022 May; 20(5):479-487.e2. PubMed ID: 35545174
[TBL] [Abstract][Full Text] [Related]
2. Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics.
John A; Shah RA; Wong WB; Schneider CE; Alexander M
Oncologist; 2020 Nov; 25(11):e1743-e1752. PubMed ID: 32627882
[TBL] [Abstract][Full Text] [Related]
3. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.
Wu N; Ge W; Quek RG; Gleeson M; Pouliot JF; Dietz H; Jalbert JJ; Harnett J; Antonia SJ
Future Oncol; 2022 Dec; 18(39):4385-4397. PubMed ID: 36656547
[TBL] [Abstract][Full Text] [Related]
4. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database.
Bhandari NR; Hess LM; He D; Peterson P
J Natl Compr Canc Netw; 2023 Sep; 21(9):934-944.e1. PubMed ID: 37673115
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
John A; Yang B; Shah R
Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.
Yang M; MacEwan JP; Boppudi SS; McClain MR; O'Hara RM; Paik PK
Cancer Med; 2023 Dec; 12(24):21605-21614. PubMed ID: 38062905
[TBL] [Abstract][Full Text] [Related]
9. Disparities in Systemic Treatment Use in Advanced-stage Non-Small Cell Lung Cancer by Source of Health Insurance.
Maguire FB; Morris CR; Parikh-Patel A; Cress RD; Keegan THM; Li CS; Lin PS; Kizer KW
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1059-1066. PubMed ID: 30842132
[TBL] [Abstract][Full Text] [Related]
10. Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer.
Stokes SM; Wakeam E; Swords DS; Stringham JR; Varghese TK
Surgery; 2018 Dec; 164(6):1287-1293. PubMed ID: 30170821
[TBL] [Abstract][Full Text] [Related]
11. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
Sheinson DM; Wong WB; Flores C; Ogale S; Gross CP
JCO Oncol Pract; 2021 Nov; 17(11):e1774-e1784. PubMed ID: 34043456
[TBL] [Abstract][Full Text] [Related]
12. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
13. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy.
Ramagopalan S; Leahy TP; Ray J; Wilkinson S; Sammon C; Subbiah V
BMC Med; 2021 Sep; 19(1):209. PubMed ID: 34521405
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.
Castellanos EH; Orlando A; Ma X; Parikh RB; O'Connell G; Meropol NJ; Hamrick J; Adamson BJS
JCO Oncol Pract; 2020 Oct; 16(10):e1216-e1221. PubMed ID: 32496874
[TBL] [Abstract][Full Text] [Related]
15. The Insurance Coverage Paradox - Characterizing Outcomes among Dual-Eligible Hemorrhagic Stroke Patients.
Pierre-Louis YS; Perla KMR; Perez GM; Jean-Charles S; Tang O; Nwaiwu CA; Weil R; Shah NS; Heffernan DS; Moreira C;
J Clin Neurosci; 2022 Mar; 97():99-105. PubMed ID: 35074583
[TBL] [Abstract][Full Text] [Related]
16. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
[TBL] [Abstract][Full Text] [Related]
17. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Low-Value Care in Medicaid vs Commercially Insured Populations.
Charlesworth CJ; Meath TH; Schwartz AL; McConnell KJ
JAMA Intern Med; 2016 Jul; 176(7):998-1004. PubMed ID: 27244044
[TBL] [Abstract][Full Text] [Related]
19. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors.
Markt SC; Lago-Hernandez CA; Miller RE; Mahal BA; Bernard B; Albiges L; Frazier LA; Beard CJ; Wright AA; Sweeney CJ
Cancer; 2016 Oct; 122(20):3127-3135. PubMed ID: 27500561
[TBL] [Abstract][Full Text] [Related]
20. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
